Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Projected Market Size and Growth Rates for the Prothrombin Complex Concentrate Market From 2025 To 2029?

The market size of prothrombin complex concentrate has seen substantial progress in the past few years. The market value is set to increase from $1.29 billion in 2024 to $1.38 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.7%. The remarkable growth during the historical period is primarily attributed to the upsurge in bleeding disorders’ prevalence, the expansion in the use of warfarin reversal, the increasing cognizance regarding coagulation treatments, the broadening scope of surgical procedures and the inflating cases of trauma.

The market for prothrombin complex concentrate is projected to experience robust expansion in the coming years. It is forecasted to reach $1.83 billion in 2029, with a compound annual growth rate of 7.3%. This predicted rise during the forecast period is associated with an increased demand for quick coagulation treatments, a surge in hemophilia and liver disease incidence, a growing use in emergency medicine, broader usage in heart surgeries, and escalating healthcare spending. Key market trends over the forecast period encompass the incorporation of AI-powered diagnostics, progress in recombinant coagulation factors, the advent of next-generation recombinant pccs, personalized dosing algorithms, and improvements in blood plasma products.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23488&type=smp

Which Primay Drivers Are Accelerating Growth in the Prothrombin Complex Concentrate Market?

An uptick in the occurrence of bleeding disorders is predicted to stimulate the advancement of the prothrombin complex concentrate market. Bleeding disorders, which cause abnormal blood clotting that can lead to excessive bleeding due to faulty or missing clotting factors or platelets, are experiencing growth primarily due to the escalating incidence of genetic conditions like hemophilia, a rise in liver disease cases, increased use of anticoagulant medications, and an elevated rate of vitamin K deficiencies. Prothrombin complex concentrate combats bleeding disorders by quickly replenishing clotting factors, critical elements for successful blood coagulation and hemostasis. For example, in November 2023, the U.S.-based National Library of Medicine reported on a study from 2022 involving 10,276 persons with hemophilia, carried out in 87 treatment centers across 40 countries. Approximately 49% of these participants had severe hemophilia, 99% were male, and 85% were diagnosed with hemophilia A. Also, 67% of the patients hailed from low and medium-income countries. Therefore, the surging incidence of bleeding disorders is fuelling the expansion of the prothrombin complex concentrate market.

Which Primary Segments of the Prothrombin Complex Concentrate Market Are Driving Growth and Industry Transformations?

The prothrombin complex concentratemarket covered in this report is segmented –

1) By Product: 3-Factor Prothrombin Complex Concentrates; 4-Factor Prothrombin Complex Concentrates; Other Products

2) By Indication: Haemorrhagic Episodes In Factor IX Deficiency (Haemophilia B); Trauma; Life-Threatening Coagulopathy With Acute Bleeding; Warfarin-Associated Acute, Life-Threatening Bleeding; Non-Warfarin Anticoagulant Reversal With Acute Bleeding

3) By Route Of Administration: Intravenous; Subcutaneous; Intramuscular

4) By End-Use: Hospital And Ambulatory Surgical Centers; Specialty Clinics; Other End Users

Subsegments:

1) By Type: Low-Dose 3-Factor Prothrombin Complex Concentrates (PCC); High-Dose 3-Factor Prothrombin Complex Concentrates (PCC); Lyophilized 3-Factor Prothrombin Complex Concentrates (PCC)

2) By Type: Low-Dose 4-Factor Prothrombin Complex Concentrates (PCC); High-Dose 4-Factor Prothrombin Complex Concentrates (PCC); Activated 4-Factor Prothrombin Complex Concentrates (PCC)

3) By Type: Recombinant Coagulation Factor Complexes; Plasma-Derived Coagulation Factor Complexes; Combination Therapy Products

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=23488&type=smp

Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Prothrombin Complex Concentrate Market?# Market?

North America was the largest region in the prothrombin complex concentrate market in 2024. The regions covered in the prothrombin complex concentrate market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Technological Trends Are Reshaping the Prothrombin Complex Concentrate Industry Dynamics?

Leading companies in the prothrombin complex concentrate market are focusing on innovation in formulations like the lyophilized powder to boost stability, streamline administration procedures, and enhance the storage ability. Lyophilized powder, which is a formulation that eliminates water by freeze-drying, results in a longer shelf life and sustains potency, enabling more efficient storage and swift reconstitution during emergencies. For instance, Octapharma USA Inc., an American biotech firm, received clearance from the FDA for Balfaxar, a 4F-PCC for immediate Warfarin reversal during surgeries and invasive procedures, in July 2023. The approval came on the back of the LEX-209 trial, which demonstrated a 94.6% hemostatic efficacy, establishing it as equitably effective as Kcentra. This progress highlights the sector’s commitment to enhance coagulation treatments for better patient results in intense care situations.

View the full report here:

https://www.thebusinessresearchcompany.com/report/prothrombin-complex-concentrate-global-market-report

What Parameters Are Used to Define the Prothrombin Complex Concentrate Market?

Prothrombin complex concentrate (PCC) is a medication containing clotting factors used to treat or prevent bleeding in patients with coagulation disorders. It is administered intravenously to rapidly restore clotting factor levels in conditions such as hemophilia, warfarin reversal, and severe bleeding episodes.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23488

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model